Please login to the form below

Not currently logged in
Email:
Password:

Onivyde

This page shows the latest Onivyde news and features for those working in and with pharma, biotech and healthcare.

Shire offloads oncology unit to Servier for $2.4bn

Shire offloads oncology unit to Servier for $2.4bn

Shire offloads oncology unit to Servier for $2.4bn. The French drugmaker will also acquire Oncaspar and Onivyde as part of the deal. ... The Dublin-based company said the deal covers its already-marketed drug Oncaspar (pergaspargase) for acute

Latest news

  • NICE knocks-back Shire's pancreatic cancer drug Onivyde NICE knocks-back Shire's pancreatic cancer drug Onivyde

    NICE knocks-back Shire's pancreatic cancer drug Onivyde. Final guidance rules it's not a cost-effective use of NHS resources. ... NICE has ruled that Shire’s pancreatic cancer drug Onivyde (pegylated liposomal irinotecan) is not a cost-effective use of

  • Ipsen buys cancer business from stripped down Merrimack Ipsen buys cancer business from stripped down Merrimack

    Ipsen buys cancer business from stripped down Merrimack. Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval. ... French drugmaker Ipsen will pay $575m to buy Merrimack Pharma's oncology business, headed by

  • Shire wins EU licence for pancreatic cancer drug Onivyde Shire wins EU licence for pancreatic cancer drug Onivyde

    Shire wins EU licence for pancreatic cancer drug Onivyde. Combination treatment is the first approved for this patient population. ... As such Onivyde marks a first for this indication of pancreatic cancer patients for whom there has been little

  • HIV prevention pill heads July CHMP recommendations HIV prevention pill heads July CHMP recommendations

    The CHMP also gave a positive opinion for Shire's Onivyde (pegylated irinotecan liposomal formulation) for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin,

  • FDA approves Merrimack's pancreatic cancer drug FDA approves Merrimack's pancreatic cancer drug

    FDA approves Merrimack's pancreatic cancer drug. Onivyde improves overall survival rates. ... The FDA has approved Merrimack's Onivyde for the treatment of advanced pancreatic cancer.

More from news
Approximately 5 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    At the start of this year it acquired Merrimack’s oncology business, including Onivyde (liposomal irinotecan), for $575m. ... Also on Ipsen’s radar are opportunities in pancreatic cancer, where it’s keen to maintain the momentum gained from

  • Deal Watch January 2017 Deal Watch January 2017

    Acquisition - asset| product| portfolio. Onivyde irinotecan liposome injection. 1, 025.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics